Nanjing Pharmaceutical: The GPHL Phase II Fund has obtained approval to acquire 11.04% of Nanjing Pharmaceutical's shares.

Nanjing Pharmaceutical Notice, recently, the company received a notification letter from Guangzhou Pharmaceutical Second Phase Fund. Guangzhou Pharmaceutical Second Phase Fund has obtained approval from its state-owned assets regulatory unit Guangzhou Pharmaceutical Group Co., Ltd. for the transfer of 11.04% shares of Nanjing Pharmaceutical Co., Ltd. by Guangzhou Pharmaceutical Group about Guangzhou Guangzhou Second Phase Fund equity investment partnership acquisition. The approval allows Guangzhou Pharmaceutical Second Phase Fund to acquire 1.45 billion shares of non-restricted shares held by Alliance Healthcare in Nanjing Pharmaceutical through an agreement transfer, accounting for 11.04% of Nanjing Pharmaceutical's total share capital on the day of signing the "Strategic Investment Agreement". The transfer price is 749 million yuan.